To understand the cellular mechanism underlying the observed therapeutic effect of pIL-12 GET therapy, we further analyzed the immune response in the B16F10 melanoma model, which represents an immunosuppressive tumor microenvironment with low expression of MHC class I (MHC-I) molecules and high PDL1 expression (Figure S2). Here, CD274 is linked to melanoma.